Results. The overall prevalence of gout was 24.3%, and increased from 16 .0% in those with eGFR ≥60 mL/min/1.73 m 2 to 35.6% in those with eGFR <30. Of those with self-reported gout, 30 .7% of individuals were not currently taking any gout medication and among gout patients on urate lowering therapy, 47.2% still showed hyperuricaemia. Factors associated with gout were serum urate, lower eGFR, advanced age, male sex, higher body mass index and waist-to-hip ratio, higher triglyceride and C-reactive protein (CRP) concentrations, alcohol intake and diuretics use. While lower eGFR categories showed significant associations with gout in multivariableadjusted models (prevalence ratio 1.46 for eGFR <30 compared with eGFR ≥60, 95% confidence interval 1.21-1.77), associations between gout and higher urinary albumin-to-creatinine ratio in this CKD population were not significant. Conclusions. Self-reported gout is common among patients with CKD and lower GFR is strongly associated with gout. Pharmacological management of gout in patients with CKD is suboptimal. Prospective follow-up will show whether gout and hyperuricaemia increase the risk of CKD progression and cardiovascular events in the GCKD study.
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I N T R O D U C T I O N
Gout is a common and painful inflammatory arthritis [1] [2] [3] , caused by urate crystal deposition in tissues and joints when local concentrations of urate exceed its physiological solubility threshold [4] . The burden of gout in the general population is increasing worldwide [5] [6] [7] [8] , with reported prevalence between 0.53 and 6.1% [9] . Due to the high morbidity, treatment and consequences associated with gout, this inflammatory arthritis poses a substantial financial burden to the health-care system [10, 11] . The management of gout is reported to be suboptimal [5] , and a better understanding of the pathophysiology of gout and its correlates is a first step to improve diagnosis and treatment.
Correlates for gout have been examined in numerous studies. The most clinically relevant correlates are male sex, obesity, the metabolic syndrome and its components, dietary factors, hypertension and the current use of diuretics [12] [13] [14] [15] [16] [17] [18] [19] . Reduced kidney function leads to accumulation of urate in the blood since renal elimination is the main endogenous mechanism of regulating serum urate concentrations [20] . Numerous studies have demonstrated that hyperuricaemia is associated with a reduced estimated glomerular filtration rate (eGFR) in population-based settings, and one study suggested that adults with eGFR <60 mL/min/1.73 m 2 are at a 2-fold increased risk of developing hyperuricaemia [21] . However, only a limited number of studies have investigated gout in individuals with chronic kidney disease (CKD), although they represent a high-risk population for the condition [22] [23] [24] . Moreover, many studies only evaluated the effect of reduced eGFR on the risk of hyperuricaemia or gout [7, 25] , whereas the urinary albumin-to-creatinine ratio (UACR) is also used to define CKD [26] . Of previous population-based studies, an association between higher albuminuria and the prevalence or risk of gout or hyperuricaemia has been reported in some [22] but not all studies [27] . In CKD populations, levels of albuminuria are typically much higher compared with the general population. Thus, the study of gout in populations with CKD and specifically the relationship of both eGFR and albuminuria with gout deserve further investigation.
We therefore examined the prevalence, correlates and management of gout in a large cohort of 5085 participants of the German Chronic Kidney Disease (GCKD) study. Our objectives were (i) to quantify the prevalence of hyperuricaemia and gout as well as their pharmacological treatment; (ii) to assess the association of both kidney function parameters eGFR and UACR and the underlying cause of disease with the prevalence of gout and serum urate levels/hyperuricaemia and (iii) to identify correlates of gout in the setting of CKD that may be modifiable.
M AT E R I A L S A N D M E T H O D S

Study population
The GCKD study is an ongoing prospective observational study. To systematically investigate correlates and consequences of CKD, 5217 Caucasian patients aged 18-74 years with an eGFR ranging from 30 to 60 mL/min/1.73 m 2 or overt proteinuria in the setting of eGFR >60 mL/min/1.73 m 2 were enrolled across Germany between 2010 and 2012 as described previously [28] . Patients provided written informed consent, and the study was approved by the Ethics Boards of all nine participating study centres. For the present study, we analysed data from 5085 patients with non-missing values for self-reported gout, urate measurements, eGFR and UACR at the baseline visit.
Assessment of gout
Gout status was ascertained through a standardized interview administered by trained interviewers. Gout was considered present when a patient gave an affirmative answer to the question 'have you ever been told by a physician that you have gout?' Self-reported gout has been described as reliable in previous epidemiologic studies in the general population [29] . Uric acid was measured from serum using an enzymatic colorimetric test (UA Plus, Roche/Hitachi Diagnostics GmbH, Mannheim, Germany). Hyperuricaemia was defined as >420 µmol/L (7 mg/ dL) in men and >357 µmol/L (6 mg/dL) in women [22, 30] .
Glomerular filtration rate and albuminuria Serum and urine creatinine were measured using the CREA plus (Roche/Hitachi Diagnostics GmbH, Mannheim, Germany) assay and urine albumin using the ALBU-XS assay (Roche/ Hitachi Diagnostics GmbH, Mannheim, Germany). Estimated GFR was calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration formula [31] . The UACR (mg/g) was based on urine albumin (mg/dL)/urine creatinine (g/dL). According to the Kidney Disease: Improving Global Outcomes CKD guidelines [26] , GFR categories were defined as follows: ≥60 mL/min/1.73 m 2 (G1/2), 45-59 (G3a), 30-44 (G3b) and <30 (G4/5), while UACR was categorized into A1 (<30 mg/g, normoalbuminuria), A2 (30-<300 mg/g, microalbuminuria) and A3 (≥300 mg/g, macroalbuminuria).
Assessment of renal diagnosis
To obtain information on the underlying cause of CKD, the patient's treating nephrologists were asked to choose from a given list of aetiologic categories, which were summarized into the groups diabetic nephropathy, nephrosclerosis, primary glomerular disease, interstitial nephropathy, acute kidney injury, systemic diseases, solitary kidney, hereditary diseases, obstructive urophathy or miscellaneous.
Assessment of demographic, anthropometric and medical covariates Age, gender and menopausal status were recorded at study entry, and weight, height, waist, hip circumference and blood pressure (BP) were measured by trained and certified study personnel in a standardized way. BP was measured three times after 5 min of rest in a sitting position using Omron M5 Professional devices (article number: Art.-Nr. HEM-7213-D, http://www.omron-medizintechnik.de/). Uric acid, cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein (CRP) and other laboratory parameters were measured in a central laboratory from blood and urine collected at the enrolment visit. Every medication currently taken by a patient was recorded, and active ingredients were coded using the latest Anatomical Therapeutic Chemical (ATC) codes (http:// www.wido.de/amtl_atc-code.html, version for 2013). The intake of gout medication was based on the codes M04AA, M04AB, M04AC, M04AH and M04AX. Codes C09A and C09B were used to define angiotensin-converting enzyme inhibitor intake, and C03 represented diuretics intake.
Body mass index (BMI, kg/m 2 ) was calculated from patient weight and height, and obesity was defined as BMI >30 kg/m 2 . Waist-to-hip ratio (WHR) was calculated from measured values. Systolic and diastolic BP was calculated as the mean of three measurements per person, where hypertension was defined as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg and/or use of antihypertensive medications. Diabetes was defined as HbA1c ≥6.5% or current use of at least one anti-diabetic medication. Coronary heart disease (CHD) was defined as present based on self-reported history of myocardial infarction or coronary reperfusion procedure (bypass or angioplasty). Alcohol intake was dichotomized as 'no or little' (alcohol consumption on <3 days/week) or 'moderate to large amount.'
Statistical analysis
Characteristics of the GCKD population by gout status or eGFR and UACR categories were compared using t-and χ 2 tests for continuous and categorical variables as appropriate. Variables that were clearly not normally distributed were compared across categories using Wilcoxon tests.
Gout prevalence was obtained by tabulation across categories of eGFR and UACR. Modified Poisson regression models were used to estimate prevalence ratios (PRs) [32] for gout according to kidney function measures, and compared with those from logistic regression analyses. Linear regression analyses were employed to model the relationship between uric acid and kidney function measures. All regression analyses evaluated three separate models: model 1 was unadjusted, model 2 adjusted for age, sex and study centre as covariates and model 3 included a full set of known gout correlates: age, sex, study centre, BMI, WHR, systolic BP, triglycerides, CRP, high-density lipoprotein (HDL) cholesterol, alcohol intake, diuretics use, CHD and diabetes. Among variables in model 3, triglycerides, CRP and UACR were log transformed, and WHR was examined per standard deviation (SD) increase, age per 5-year intervals and systolic BP per 10-mmHg increase. Gout medication use, cholesterol and hypertension were not included in the multivariate regression models due to high correlations with gout, HDL cholesterol and systolic BP, respectively. To allow for a direct comparison between models, the study population of models 1 and 2 was restricted to individuals with complete information for model 3.
To evaluate the impact of uric acid as a mediator of the association between kidney function and gout, additional regression models included serum urate concentrations as a covariable. Likelihood ratio tests were used to check the difference between models with and without the inclusion of serum urate concentrations and gout medication intake. Subgroup analyses were conducted across strata of gout medication intake.
Scatter and line plots were used to illustrate the correlation between uric acid and eGFR or UACR by gender. The proportion of the GCKD baseline population with gout and hyperuricaemia was illustrated across the range of eGFR using a linear spline with knots at 30, 60 and 90. In addition, the distribution of GFR and UACR by gout status and gout medication was plotted using kernel density plots. All analyses were conducted using Stata 13.0 (Stata Corp LP, College Park, TX).
R E S U LT S
Characteristics of the study population and gout medication intake The study sample characteristics of up to 5085 patients with non-missing information on gout, urate measurements, eGFR and UACR are shown in Table 1 ; overall, 1238 of 5085 patients (24.3%) reported to have gout. The prevalence, mean or median of most correlates was clearly higher in gout patients compared with those without gout. However, both serum urate concentrations and the prevalence of hyperuricaemia were similar between the two groups, which may have resulted from the higher proportion of gout medication use among CKD patients with gout compared with those without. Table 2 gives an overview of the current use of gout medications, both overall and separately for CKD patients with and without gout. Of all 5085 GCKD participants, 32.5% currently use gout medication (69.3% of those with and 20.7% of those without gout, P < 0.001), which means that approximately onethird of the patients with self-reported gout were not currently taking any gout medication. Uricostatics identified by ATC codes were by far the most common medication category, and allopurinol accounted for >97% of the uricostatic treatment. Uricosurics, especially benzbromarone, were used by few individuals (2.8% of patients with gout). Other gout medications such as tisopurine, probenecid, sulfinpyrazone and isobromindione were not used by any patient. Figure 1 shows that the proportion of patients with gout increases with lower eGFR, but even at eGFR within the normal range, a substantial fraction of patients with gout are not treated. Moreover, of all gout patients using a urate-lowering therapy, 47.2% still had hyperuricaemia. Supplementary data, Figure S1 shows that individuals not currently taking any gout medication had generally higher levels of eGFR than individuals who were taking gout medication, consistent with the prescription of gout medication in response to an increase in serum urate concentrations at lower levels of GFR. Individuals with gout had lower eGFR compared with individuals without, a finding that was observed overall and also among those not currently taking any gout medication.
Distribution of serum urate concentrations and gout prevalence
The distribution of serum urate concentrations is shown across the range of eGFR (Supplementary data, Figure S2A prediction of serum urate concentrations with the corresponding lowess smoother in Supplementary data, Figure S2 indicates that the relationship between eGFR and serum urate was approximately linear across the range of eGFR values. Whereas serum urate was higher in males than in females across the range of UACR, the sex difference for serum urate concentrations decreased with lower eGFR and was not observed anymore as eGFR approached ∼40 mL/min/1.73 m 2 . Supplementary data, Table S1A and B show baseline study characteristics by category of eGFR and UACR, respectively, and support the observation that serum urate concentrations increase with lower eGFR but not higher UACR.
Gout prevalence showed a gradual increase with lower eGFR from 16.0% among those with an eGFR >60 mL/min/1.73 m , the predictions within this range of eGFR may not be very precise. Table 3 shows that, when compared with an eGFR of ≥60 mL/ min/1.73 m 2 , the unadjusted PR of gout was significantly increased by 1.42-fold, 1.65-fold and 2.17-fold for those with an eGFR of 45-59, 30-44 and <30 mL/min/1.73 m 2 . The significant association between gout and lower eGFR persisted after adjusting for age, sex and study centre as well as upon further extensive adjustment for potential confounders for CKD stages 3b and 4/5, but the magnitude of the ratios decreased. The PR of gout by category of UACR was not significant in unadjusted analyses, and-compared with individuals with normoalbuminuria-showed modest and insignificant associations for both microalbuminuria and macroalbuminuria [PR 1.09, 95% confidence interval (CI) 0.96-1.24, Table 3 ]. Associations obtained Estimates are derived from the full model (model 3). PR: prevalence ratio, CI: confidence interval. G and A refer to the CKD stages (see Materials and Methods). The study centres Heidelberg and Aachen also showed significant association with increased gout prevalence, but adjustment was included for all study centres. from logistic regression models were similar but risk estimates were higher; therefore, the more conservative estimates from Poisson regression models are shown throughout.
Correlates of self-reported gout
To identify factors that are independently associated with gout, regression models were employed that included multiple covariates selected based on the prior literature and gout pathophysiology [9, 33] . As displayed in Table 4 , advanced age, male sex, higher BMI, WHR, triglyceride concentrations and CRP, a moderate or large amount of alcohol intake, diuretics use and some of the study centres were significantly associated with gout. Among these correlates, the strongest associations were observed for advanced age, higher BMI and male sex, followed by diuretics use and an eGFR of <30 mL/ min/1.73 m 2 (RR 1.46, 95% CI 1.21-1.77). Systolic BP, HDLcholesterol concentrations, CHD and diabetes did not show significant association with gout upon multivariable adjustment, although they showed association in univariate analyses (see Table 1 ). Higher UACR categories were not independently associated with gout, and this was true in the overall GCKD population (Table 4) For comparison, Supplementary data, Table S2 shows the corresponding estimates for serum urate concentrations. Mean serum urate concentrations showed a graded and significant increase with lower eGFR, which remained significant upon multivariable adjustment. Significant positive associations between serum urate and higher UACR were observed, but-similar to the associations with gout-were of lesser magnitude than the associations between serum urate and eGFR. To evaluate to which extent serum urate influenced the associations between gout and its correlates, serum urate was included as an additional covariable. While this had little effect in the overall study population, the association between eGFR and gout became insignificant upon adjustment for urate among those not currently using any gout medication (data not shown).
Lastly, we evaluated whether gout prevalence differed by CKD aetiology. The proportions of patients with diabetic nephropathy and nephrosclerosis were significantly higher among patients with gout compared with those without gout, consistent with the epidemiological correlation of gout with diabetes and hypertension ( Table 5 ). The prevalence of hereditary nephropathy was significantly lower among those with gout, consistent with the younger age and specific cause of disease in these patients. The addition of CKD aetiology to the multivariable-adjusted model presented in Table 4 showed that diabetic nephropathy, nephrosclerosis and hereditary nephropathy were not independently associated with gout, suggesting that the different proportion of these CKD aetiologies in patients with and without gout can be explained by one or more of the other known gout correlates such as age.
D I S C U S S I O N
This study is the first epidemiological investigation of gout prevalence among a large CKD patient population, a high-risk group for gout. The prevalence of gout was 24.3% in the overall GCKD population and increased with lower eGFR from 16.0% (eGFR of ≥60 mL/min/1.73 m 2 ) to 35.6% (eGFR <30 mL/min/ 1.73 m 2 ), highlighting the large burden of disease posed by the painful condition of gout and its sequelae. Moreover, we found evidence for significant undertreatment; ∼30% of those with gout received no uric acid lowering medication, and among those who are treated almost half remained hyperuricaemic.
The prevalence of gout in this CKD population is about 10 times greater compared with estimates reported from population-based studies and studies of individuals with normal renal function [23] . A study conducted among individuals with CKD identified in the nationally representative population-based National Health and Nutrition Examination Survey (NHANES) found a similar gout prevalence of 35% among those with stage 4 CKD, but lower gout prevalence of 11% among those with stage 3 CKD compared with our estimate of ∼25% for CKD stages 3a and 3b [22] . A potential reason for these discrepancies is that a diagnosis of CKD stage 3 based on one measurement of serum creatinine in population-based settings such as the NHANES survey is less valid than the verified presence of CKD in patients under nephrological care, the source population of the GCKD study.
Our results of an inverse relationship between eGFR and gout as well as hyperuricaemia are consistent with other studies [21] [22] [23] , but the association between albuminuria and gout is less clear. In contrast to our study, Juraschek et al. [22] found a graded positive relationship between gout and albuminuria, and Krishnan et al. [24] stated that proteinuria independently associated with increased risk of gout. A potential explanation for this discrepancy is the fact that most GCKD patients were enrolled because of an eGFR <60 mL/min/1.73 m 2 , and the finding that UACR is not an independent correlate of gout in patients with CKD stage 3 or higher may not be representative of the relationship of UACR and gout in healthy reference and/or non-CKD populations. In addition, very high UACR levels in CKD populations are often found in individuals with primary glomerular diseases, who are often younger and have CKD of auto-immune aetiology compared with older individuals with diabetes who typically have high UACR in population-based studies.
The relationship between gout and CKD is bidirectional. Although reduced kidney function can precede the development of gout [24] , gout can also adversely impact renal function [34, 35] . Elevated serum urate concentrations and medication toxicity have been postulated as factors by which these conditions can lead to reduced renal function [36] . In addition, there are numerous shared correlates between the two conditions, with prevalence of 55.4% for obesity, 46.3% for diabetes, 26.7% for CHD and 97.4% for hypertension among the patients with gout in the GCKD study. Prospective studies specifically in CKD populations including different CKD stages and detailed information on medication intake are needed to determine incidence rates and correlates of new-onset gout.
Medication to treat and prevent gout is available, but the treatment of gout was reported to be suboptimal by several studies [5, 37] . The necessity to permanently maintain serum urate levels below its saturation point means that often lifelong treatment is required and cost-effective treatments are needed. Typically, the xanthine oxidase inhibitor allopurinol is prescribed as urate-lowering therapy [38] , with other medication having less favourable side effect profiles or higher associated costs. The high proportion of patients with gout that showed hyperuricaemia despite treatment would be even higher if the therapeutic target for urate-lowering therapy (ULT) would be <6 mg/dL, a threshold suggested to be associated with the slowing of CKD progression [39] . This is also illustrated in a recent publication that-using a cut-off of 6 mg/dL in a general population-based sample-reported that half of US Americans with gout on urate-lowering therapy were still hyperuricaemic [40] , a proportion comparable with the one we report in a CKD population using a higher cut-off of >7 mg/dL in men. These numbers clearly illustrate that pharmacologic management of gout in patients with CKD is suboptimal and underscores the need to achieve better urate treatment target rates using available treatment or additional novel urate-lowering therapies. Of note, however, there is a lack of prospective interventional trials in CKD patients assessing the risk benefit relationship of urate-lowering therapy [41] . This lack of evidence may influence treatment decisions and contribute to the relatively large fraction of patients with gout that remain untreated.
The present study has several limitations. First, a goldstandard definition of gout (crystal aspiration or ACR criteria) was not available and should be obtained for future studies of gout risk in patients with CKD. The use of self-reported physician-diagnosed gout may incorporate some misclassification, which may affect prevalence estimates but should not lead to false-positive correlate associations. Second, no data on dietary intake was available, which likewise should be assessed in future studies among CKD patients. Third, our study was based on data collected at the GCKD study enrolment visit, and we can therefore not answer questions related to the temporality of the association between eGFR and gout, or between the presence of gout and incident health outcomes such as renal replacement therapy. However, this will be possible in the future once prospective data become available. Our current study provides information on the prevalence of gout and which correlates to examine, and therefore facilitates future studies on new-onset gout. Our analyses were conducted using an ethnically homogenous German population of patients with mostly stage 3 CKD at enrolment, and our findings may therefore not be generalizable to other ethnic groups or countries or individuals with other CKD stages. Because of the general health-care coverage in Germany, we believe that access to care should have little impact on our findings, which may be different in other settings. A particular strength is that our results are based on one of the largest cohorts of CKD patients worldwide, and the standardized collection of information provides a sound foundation to the evidence reported here. Because of the substantial morbidity associated with gout, our findings are potentially of high clinical relevance and should stimulate and help design future interventional trials.
In conclusion, gout is a highly prevalent comorbidity in patients with CKD, and prevalence increases with lower eGFR. A third of CKD patients with gout are not treated for the condition, and among those who are treated almost half still show hyperuricaemia. CKD patients represent a high-risk population for gout and screening for and treatment of gout in this population deserves special attention.
S U P P L E M E N TA RY M AT E R I A L
Supplementary data are available online at http://ndt.oxford journals.org.
